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During infection, human immunodeficiency virus type 1 integrase engages a number of molecules andmechanisms, both of viral and cellular origin.
In one of such instances, integrase is thought to be degraded by the N-end rule proteasome pathway a process that targets the N-terminal residue of its
substrates. Here we describe the properties of HIV-1 viruses in which the first amino acid residue of integrase has been substituted to render it resistant to
the N-end rule pathway. As result of this exchange, we observe a set of class I and class II defects that result in a large decrease of viral replication
efficiency. Specifically, reverse transcription and integration are the steps that appear to be affected. We propose that the severe deficiency of these
mutants exert a strong selective pressure that leads to the near total conservation of the N-terminal residue of integrase in HIV-1, HIV-2 and SIV.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV-1; Integrase; EGFP; N-end ruleIntroduction
Human immunodeficiency virus type 1 (HIV-1), as part of the
retrovirus family, reverse transcribes its RNA genome and
inserts the resulting cDNA into the chromosomal DNA of its
host. This last process is mediated by the viral enzyme integrase
(IN), in concert with cellular factors. In several studies
(Engelman et al., 1995; Lu et al., 2005a, 2005b, 2005c; Wisker-
chen and Muesing, 1995), the mutagenesis of conserved regions
within IN has determined its importance in the various reactions
that lead to integration (class I mutants) as well as in other steps
of the viral life cycle (class II mutants) (Engelman, 1999).
IN is the retroviral protease-dependent proteolytic product of
the Gag-Pol polyprotein, and also one of the few known
substrates for the ubiquitin/proteasome pathway known as N-
end rule (Mulder and Muesing, 2000). The N-end rule
determines the half-life of its substrates by the identity of their
first residue (Bachmair et al., 1986). In yeast, Rad6 and UBR1
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doi:10.1016/j.virol.2006.10.007pathway (Bartel et al., 1990; Dohmen et al., 1991; Madura et al.,
1993). In mammalian cells, there are two Rad6 alleles, Rad6A
and Rad6B (Koken et al., 1991), and at least 7 orthologs of
UBR1 (Tasaki et al., 2005). Mammalian UBR1–2 and 4 have
been shown to be involved in the degradation of ectopically
expressed HIV-1 IN (Tasaki et al., 2005).
The first residue of HIV-1 IN is invariably a phenylalanine
(Phe). Phe ranks as a primary instability determinant in the N-
end rule hierarchy that classifies the N-terminal residues based
on the (in)stability they provide to the rest of the protein
(Varshavsky, 1997). In this report, we determine the relevance of
the first residue of HIV-1 IN in viral infection.
Results
Replication and infectivity
In order to assess the importance of IN N-terminal residue in
HIV-1 infection, we mutated position 1 from Phe to Met, which
enhances IN half-life in an isolated system (Mulder and
Muesing, 2000). In addition, since changing the first residue
of IN also alters the reverse transcriptase (RT)-IN cleavage site
recognized by the viral protease, we made a second type of
mutant by introducing a potentially compensatory substitution,
from Leu to Met, at the C-terminal position of RT. This latter
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HIV-1 at the junction between p2 and p7 and therefore more
likely to be processed compared to the Leu|Met junction. As
control for the Met|Met mutant, we constructed a virus carrying
a Met|Phe combination.
Viral replication was monitored by infecting PBMC from
two different donors with equal amounts of either WTor mutant
HIV-1 R7/3 viruses (Fig. 2A upper), and monitoring p24 values
over a period of 21 days. As can be seen in Fig. 1A starting from
day 6 post-infection, viruses with mutant IN have 10- to 100-
fold lower replication rates than WT.
To assess if the mutant viruses have a replication defect in the
early phases of infection, TZM cells were infected with single
round vesicular stomatitis virus glycoprotein (VSV-G) pseudo-Fig. 1. Mutations of integrase N-terminal residue affect HIV-1 replication. (A) 2×10
EGFP and IN mutants, p24 values were assessed over a period of 21 days post-infectio
100ng/well and three 5-fold serial dilutions, of the WT and IN mutants of R7/3 CMV
presence of 8 μg/ml of polybrene. Infectivity was measured by flow cytometry and in
p24 of WTand IN mutant R7/3 CMV EGFP viruses were concentrated over a 20% suc
was detected with monoclonal antibody 6G5 and HIV-1 proteins with patient anti-Htyped WT and mutant R7/3 CMV EGFP viruses (Fig. 2A
middle). Fig. 1B shows that irrespective of the last residue of RT,
viruses bearing a Met N-terminal residue in IN (Met-IN) are at
least 8-fold (t-test p-value<0.05) less infectious than WT. To
assess if mutant viruses contain quantities of IN similar to wild
type and can support a correct processing of the Gag-Pol
polyprotein, equal amounts of concentrated virions were
analyzed by western blot. As is shown in Fig. 1C, WT and
mutant viruses contain comparable levels of IN, and Gag-Pol
processing was equivalent in all the viral clones. Of note, though
unlikely to play a major role, is that both viruses carrying mutant
IN present a faint band at the level of the RT-IN polyprotein (Fig.
1C first panel). In order to determine if this small amount of RT-
IN could influence infectivity, we decided to take advantage of a6 PBMCs stimulated with PHAwere infected with 50 ng p24/well of R7/3 YU2
n. (B) TZM cells plated at 40,000 cells/well in 24 well plates, were infected with
EGFP VSV-G pseudotyped virus. Infections were carried out overnight in the
dicated as percentage of EGFP positive cells 40–44 h post-infection. (C) 490 ng
rose cushion and half the amount loaded on a 10% polyacrylamide gel. Integrase
IV serum.
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which allows to uncouple the proteolytic cleavage of RT-IN from
the kinetic processing of HIV-1 polyproteins and from reverse
transcription. In this system, the pLR2P-R-PC-IN plasmid
(Fig. 2A lower) is used to ectopically express IN in the virus
producer cell as a fusion with Vpr, which mediates proper
incorporation and a short C-terminal stretch of RT encoding the
RT-IN cleavage site. We complemented R7/3 CMV EGFP
viruses lacking IN with the pLR2P-R-PC-IN plasmid encoding
WT IN or its mutants. Fig. 2B shows that, although infectivity
is generally low, viruses with Met-IN are 4- to 5-fold (t-test
p-values 0.0032 and 0.017, respectively) less infectious than
the WT IN carrying controls. Also in this case, the quantities
of IN present in the different virions are comparable (Fig. 2C).
Taken together, these results show that the identity of the N-
terminal residue of IN plays a significant role in HIV-1
infectivity, and that its influence exceeds that dictated by the
optimal composition of the RT-IN proteolytic cleavage site.
Effect of IN N-terminal residue on reverse transcription
In order to determine which step between entry and inte-
gration is affected by the identity of the N-terminal residue of IN,
we quantified the reverse transcription product of the different
viruses at distinct time points. Viral cDNA was measured byFig. 2. Reduced replication of integrase N-terminal mutant viruses is not due to a
Concentrated R7/3 CMV EGFP ΔIN VSV-G pseudotyped viruses complemented wi
Infectivity was measured by flow cytometry and indicated as percentage of EGFP p
VSV-G pseudotyped virions complemented with pLR2P-R-PC-IN and IN mutant
monoclonal antibody 6G5.fluorescent quantitative PCR (qPCR) using primers specific for
late reverse transcription products. Fig. 3 shows that Met-IN
bearing viruses consistently exhibit a 2.5- to 5-fold (t-test p-
value<0.01) reduced amount of late reverse transcription
product than Phe-IN bearing viruses. These results suggest
that the identity of the N-terminal residue of IN influences the
synthesis or the accumulation of viral cDNA.
Effect of IN N-terminal residue on integration
We next asked whether viruses with mutant INs are
competent for integration or if a defect in this process could be
an additional cause for their overall lower infectivity.We used an
R7/3 CMV EGFP virus carrying an IN with a D116A active site
substitution and complemented it with the pLR2P-R-PC-IN
vector or its N-terminal mutants. Fig. 4A shows that IN N-
terminal mutants are only partially able to complement the
catalytically inactive IN molecule of the backbone virus, with a
2- to 3-fold lower number of cells harboring the integrated
provirus. Given that D116A IN mutant viruses are fully
proficient for reverse transcription and that recombinant HIV-1
IN with an N-terminal Met is competent to perform concerted
integration reactions in vitro, these results could arise from two
causes: the most direct is that IN N-terminal mutants are less
proficient in the integration reaction in vivo, but it is alsoRT-IN cleavage defect. (A) Diagrams of the constructs used in this work. (B)
th pLR2P-R-PC-IN and IN mutants were used to infect 40,000 TZM cells/well.
ositive cells 40–44 h post-infection. (C) Concentrated R7/3 CMV EGFP Δ IN
s were separated on a 10% polyacrylamide gel. Integrase was detected with
Fig. 3. Integrase N-terminal mutant viruses have a defect in the accumulation of
cDNA. Cells were infected with 100 ngWTand INmutants of R7/3 CMVEGFP
VSV-G pseudotyped virus for 5 h and late reverse transcripts were assessed by
qPCR at 5, 10 and 25 h after infection.
Fig. 4. N-terminal mutant integrase only partially rescues integration-deficient
HIV-1. (A) TZM cells were infected with pLR2P-R-PC-IN and IN mutants
complemented R7/3 CMV EGFP D116AVSV-G pseudotyped viruses, split 1:10
and assessed by flow cytometry at 2, 6 and 10 days after infection. (B) TZM
cells were infected with pLR2P-R-PC-IN and IN mutants complemented R7/3
CMV EGFP and R7/3 CMV EGFP D116AVSV-G pseudotyped viruses for 5 h
and late reverse transcripts were assessed by qPCR at 10 h after infection.
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on reverse transcription, which would result in less substrate for
integration. Since our previous results evidenced an influence of
the N-terminal residue of IN on the accumulation of RT product,
we quantified the amount of viral cDNA synthesized after
infection withWTand D116Aviruses complemented with either
N-terminal Met IN or WT IN. Fig. 4B shows that levels of late
RT product are comparable between viruses complemented
either with WT IN or its N-terminal Met mutant (t-test p>0.05),
and a 2- to 4-fold lower amount of late RT product in the
complemented viruses compared to the non-complemented ones
regardless of the identity of the N-terminal residue. These results
indicate that an excess of IN has a detrimental effect on reverse
transcription and that under these conditions theMet-IN does not
add to the negative effect compared to WT IN likely because the
amount of complementing WT IN is enough to overwhelm the
system and accordingly overshadow any further effect due to IN
stabilization. Taken together, these data indicate that substitution
of the N-terminal residue of HIV-1 IN results in the inability of
the mutants to efficiently fulfill the integration step.
Discussion
Alongside RT, IN is the enzyme that distinguishes retro-
viruses from other viruses. IN belongs to a family of structurally
related DNA transferases that includes phage transposases and
mammalian VDJ recombinases RAG1 and RAG2. Recombinant
HIV-1 IN has been shown to mediate a concerted in vitro
integration reaction without any additional protein (Sinha et al.,
2002). Recently, a number of host factors that interact with INhave been identified. Lens epithelium-derived growth factor
(LEDGF) p75 has been identified as a primary IN binding pro-
tein (Cherepanov et al., 2003). The binding is lentiviral specific
(Busschots et al., 2005; Llano et al., 2004) and LEDGF appears
to tether IN to the host chromosomal DNA (Vanegas et al.,
2005), thereby playing a role in site selection (Ciuffi et al., 2005)
as well as facilitating integration (Vandekerckhove et al., 2006).
We have shown that HIV-1 IN interacts with DNA repair
protein Rad18 (Mulder et al., 2002), and that cells lacking Rad18
are more permissive to viral infection (Lloyd et al., 2006).
HIV-1 IN is a substrate of theN-end rule proteasome pathway,
in which the stability of a protein is determined by the identity of
its N-terminal residue (Bachmair et al., 1986). HIV-1 IN is the
product of the proteolytic cleavage of Gag-Pol and has at its
N-terminus a Phe, a highly destabilizing residue in the N-end
133A.G. Lloyd et al. / Virology 360 (2007) 129–135rule. We therefore set out to test the relevance of this residue in
the context of the HIV-1 early life cycle.
The results of our study indicate that the identity of IN
N-terminal residue is of great importance as its substitution
causes a near total inhibition of viral replication (Fig. 1A). This
outcome is the result of multiple defects mainly residing in the
early phases of infection (Fig. 1B) and involving both reverse
transcription (Fig. 3) and integration (Fig. 4A). Evidences for a
role of IN in reverse transcription have previously been
described. Specifically, it has been demonstrated that IN and
RT directly interact in vitro (Tasara et al., 2001; Wu et al., 1999)
and that a number of mutations in conserved regions of IN
induce severe defects in viral cDNA synthesis (Ao et al., 2005;
Lu et al., 2005a, 2005c; Wu et al., 1999). Our data imply that the
identity of HIV-1 IN N-terminal residue influences reverse
transcription and also suggest that because of the nature of the
substitution analyzed such relevance might be related to the
stability of integrase via the N-end rule proteasome pathway, as
we reported earlier (Mulder and Muesing, 2000). Whether and
how IN increased stability harms reverse transcription or the
half-life of its product is currently under investigation. We
speculate that higher concentrations of IN could directly inhibit
RT as suggested by Tasara et al. (2001), this is supported by the
results shown in Fig. 4B, where an excess of IN (from a
complementation system in trans) decreased the amount of RT
products. Alternatively, IN could be the target of host factors that
can prevent it from efficiently carrying out its pro-reverse
transcription activity.
The mechanism of integration inhibition by Met-IN is still
unknown. Given that concerted integration can be efficiently
achieved in vitro by recombinant Met-IN (Sinha et al., 2002),
we hypothesize that increased stability of integrase might be
detrimental for the repair of the single-stranded gap left after the
insertion of the retroviral genome into the chromosomal DNA.
Indeed, the prompt degradation of the integration complex
might be necessary to allow the access of host derived DNA
repair factors devoted to the closing of the gap. In this regard, it
has been demonstrated that an excess of retroviral IN inhibits
the access of repair polymerases to DNA gap repair reactions in
vitro (Yoder and Bushman, 2000).
In conclusion, we describe here that substitutions of the first
residue of HIV-1 IN originate viruses with a complex phenotype,
that can be classified both as class I mutants (Engelman, 1999),
because of their inability to fully restore integration of integra-
tion-inactive viruses, as well as class II mutants because of their
defect in the reverse transcription step. It is therefore not
surprising, given the pleiotropic defects of the N-terminal IN
mutant viruses, that the identity of IN first residue is almost
absolutely conserved in HIV-1, HIV-2 and SIV (source: Los
Alamos National Laboratory HIV Database).
Materials and methods
Plasmids and virus production
R7/3 YU2 EGFP (Wiskerchen and Muesing, 1995) (Fig. 2A,
upper) was derived from the R7/3 HIV-1 clone (Feinberg et al.,1986) in which EGFP was cloned in the Nef position and the
original envelope exchanged with an YU2 Env gene. R7/3 CMV
EGFP (Fig. 2A middle) was constructed by cloning the CMV
EGFP expression cassette into the ENV position of the R7/3
clone. Vesicular stomatitis virus glycoprotein (VSV-G) was ex-
pressed from plasmid phCMV G (Yee et al., 1994). IN comple-
mentation vector pLR2P-R-PC-IN (Fig. 2A lower) was
described earlier (Fletcher et al., 1997). IN point mutations
were made by overlap PCR and using standard molecular
biology techniques.
Viral stocks were made by transfecting HEK 293T with
polyethylenimine (PEI) (Polysciences Inc.) (Durocher et al.,
2002). Supernatants were harvested 40–44 h later, 0.45 μm
filtered, aliquoted and frozen at −70 °C. HIV-1 was quantified
by p24 ELISA performed using the HIV-1 p24 Antigen EIA kit
(Beckman Coulter). Virus concentration was obtained by
loading equal amounts of the different viruses on a 20% sucrose
cushion and then centrifuging at 20,000×g for 3 h at 4 °C for
experiments of Fig. 1C or at 35,000×g for 1.5 h at 4 °C for
experiments of Figs. 2B and C.
Infectivity analysis and western blot
For spreading infections experiments, 2×106 PHA stimu-
lated PBMCs from two different donors were infected overnight
with 50 ng p24/well of R7/3 YU2 EGFP and its IN mutants in a
24-well plate, washed three times with PBS and re-fed with
complete RPMI-1640 medium plus 40 units IL-2/ml, super-
natant's p24 values were assessed at day 4, 6, 11, 13, 18 and 21
days post-infection.
TZM cells were obtained through the AIDS Research and
Reference Program, Division of AIDS, NIAID, NIH, from Dr. J.
Kappes.
For single round infections, TZM cells were plated in 24 well
plates at 40,000 cells/well and infected with serial dilutions of
the WT as well as of the IN mutant viruses. Infections were
carried out overnight in the presence of 8 μg/ml of polybrene.
The second day after infection cells were trypsinized, fixed with
PBS 3% formaldehyde (Tousimis) and fluorescence was
analyzed by flow cytometry using FACScalibour (Becton
Dickinson). 20,000 events were acquired per sample.
Integration was assessed by using an integration-defective
R7/3 CMV EGFP virus carrying an IN with a substitution at
position D116 and complemented with the pLR2P-R-PC-IN
vector or its N-terminal mutants. We infected TZM cells and
split them 1:10 at day 2, 6 and 10 post-infection in order to
dilute the unintegrated viral cDNA. At the same time points,
aliquots of the infected cells were analyzed by flow cytometry
for EGFP expression.
Western blots were carried out by separating equal amounts
of concentrated virions, lysed in 4× loading buffer, on a 10%
polyacrylamide gel (NuPAGE, Invitrogen). Proteins were then
transferred to a PVDF membrane (Immobilon, Millipore) and
probed either with anti-IN monoclonal antibody 6G5 (Nilsen et
al., 1996) or with an HIV-1 patient serum. Membranes were
then incubated with horseradish peroxidase-conjugated sec-
ondary antibodies and developed with SuperSignal West Pico
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(anti-IN).
Quantitative PCR
TZM cells plated at a density of 40,000 cells/well were
infected with 100 ng/well of VSV-G pseudotyped R7/3 CMV
EGFP reporter virus and its IN mutants previously treated with
150 units/ml of DNase I (Roche) for 30 min at 37 °C. Infections
were carried out for 5 h in the presence of 8 μg/ml of polybrene.
After rinsing with PBS, cells were fed with complete medium.
Cells were harvested at time points 5, 10 and 25 h post-infection,
pelleted and frozen at −70 °C. Total genomic DNA was
extracted using QIAamp DNA Blood kit (Qiagen). Two
microliters of each sample was used for qPCR. Primers used
for the detection of late reverse transcription products were the
following: primer GAG-3 CAGCATTATCAGAAGGAGCCAC
and GAG-4 ATGTCACTTCCCCTTGGTTCTCT. SYBR green
(Molecular Probes) was used as reporter fluorophore and reac-
tions and acquisitions were performed using 7500 Real Time
PCR System (Applied Biosystems). Normalization was carried
out by measuring the DNA concentration of each sample using
PicoGreen dsDNA Quantitation Reagent (Molecular Probes)
following manufacturers instructions. Data are presented as
number of late reverse transcription molecules per nanogram of
total genomic DNA.
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